Nuvation Bio (Nuvation Bio) Change In Receivables : $-0.72 Mil (TTM As of Sep. 2021)

View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Change In Receivables?

Nuvation Bio's change in receivables for the quarter that ended in Sep. 2021 was $0.18 Mil. It means Nuvation Bio's Accounts Receivable declined by $0.18 Mil from Jun. 2021 to Sep. 2021 .

Nuvation Bio's change in receivables for the fiscal year that ended in Dec. 2020 was $0.00 Mil. It means Nuvation Bio's Accounts Receivable stayed the same from . 20 to Dec. 2020 .

Nuvation Bio's Accounts Receivable for the quarter that ended in Sep. 2021 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Nuvation Bio's liquidation value for the three months ended in Sep. 2021 was $763.36 Mil.

Nuvation Bio Change In Receivables Historical Data

The historical data trend for Nuvation Bio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Change In Receivables Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Change In Receivables

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Change In Receivables	Get a 7-Day Free Trial			-	0.08	-0.98	0.18	-

Nuvation Bio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.72 Mil.

Nuvation Bio (NYSE:NUVB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Nuvation Bio's Days Sales Outstanding for the quarter that ended in Sep. 2021 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Nuvation Bio's accounts receivable are only considered to be worth 75% of book value:

Nuvation Bio's liquidation value for the quarter that ended in Sep. 2021 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	791.784	-	28.425	+	0.75 * 0	+	0.5 * 0
=	763.36

Nuvation Bio Change In Receivables Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.